BiCE (Bispecific DC-T Cell Engager)

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

BiCE (Bispecific DC-T Cell Engager)

Jan 26, 2024, 07:25 | Drugs

Emma Vidal: A new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy

Emma Vidal, Founder of DrawImpacts, shared an X post by Rony Dahan, Principal Investigator at…

All: 1 Posts: 1 - 100

'

Dr. Manette Le Grange joins OncoDaily Editorial Board

'

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

'

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

'

Highlights from TTLC2025

'

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023